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ARTICLE
PTP4A1 promotes TGFβ signaling and fibrosis in
systemic sclerosis
Cristiano Sacchetti1,2, Yunpeng Bai3, Stephanie M. Stanford1,2, Paola Di Benedetto4, Paola Cipriani4,
Eugenio Santelli1,2, Sonsoles Piera-Velazquez5, Vladimir Chernitskiy6, William B. Kiosses7, Arnold Ceponis1,
Klaus H. Kaestner8, Francesco Boin6, Sergio A. Jimenez5, Roberto Giacomelli4, Zhong-Yin Zhang3
& Nunzio Bottini1,2
Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of skin and
internal organs. Protein tyrosine phosphatases have received little attention in the study of
SSc or fibrosis. Here, we show that the tyrosine phosphatase PTP4A1 is highly expressed in
fibroblasts from patients with SSc. PTP4A1 and its close homolog PTP4A2 are critical pro-
moters of TGFβ signaling in primary dermal fibroblasts and of bleomycin-induced fibrosis
in vivo. PTP4A1 promotes TGFβ signaling in human fibroblasts through enhancement of ERK
activity, which stimulates SMAD3 expression and nuclear translocation. Upstream from ERK,
we show that PTP4A1 directly interacts with SRC and inhibits SRC basal activation inde-
pendently of its phosphatase activity. Unexpectedly, PTP4A2 minimally interacts with SRC
and does not promote the SRC–ERK–SMAD3 pathway. Thus, in addition to defining PTP4A1
as a molecule of interest for TGFβ-dependent fibrosis, our study provides information
regarding the functional specificity of different members of the PTP4A subclass of
phosphatases.
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Systemic sclerosis (SSc) is a multi-system autoimmune con-nective tissue disorder that leads to fibrosis of the skin andinternal organs, resulting in substantial patient morbidity
and mortality. At present, SSc is classified in two forms, the
limited cutaneous (lcSSc) and the diffuse cutaneous (dcSSc),
which differ in the extent of cutaneous involvement1. Similar to
other fibrotic diseases, the pathogenesis of fibrosis in SSc involves
activation of fibroblasts, which leads to excessive deposition of
extracellular matrix components and differentiation of α-smooth
muscle actin (αSMA) expressing myofibroblast2, 3. Fibroblasts
and myofibroblasts are considered important target cells for
therapeutic interventions aimed at preventing and reversing
fibrosis in SSc and other fibrotic diseases2, 3. Activation of the
transforming growth factor β (TGFβ) pro-fibrotic signaling
pathway in fibroblasts is believed to have an important function
in SSc and fibrosis in general4, 5. Fresolimumab, an antibody able
to block signaling through all isoforms of TGFβ, is currently in a
clinical trial for SSc6.
Inhibitors of protein tyrosine kinases are also being extensively
investigated as potential anti-fibrotic agents in SSc7. For example,
nintedanib, a protein tyrosine kinase inhibitor approved by the
FDA for idiopathic pulmonary fibrosis8, has shown promising
results in experimental models of SSc9. By contrast, the potential
profibrotic or antifibrotic effects of protein tyrosine phosphatases
(PTP), enzymes that counterbalance protein tyrosine kinases in
signal transduction by dephosphorylating phosphotyrosine resi-
dues, are mostly unknown, both in SSc and other fibrotic dis-
orders. Aside from pioneer studies showing that the
phosphoinositide phosphatase PTEN displays reduced expression
in SSc dermal fibroblasts (DF)4, 10, only the oxidative inhibition of
the tyrosine-specific phosphatase PTP1B has been shown to be
involved in promoting platelet-derived growth factor signaling in
SSc fibroblasts11. Some PTPs have been reported to modulate
TGFβ signaling: for example, SHP-2 and PTPRA enhance TGFβ
signaling, although their mechanism of action has not yet been
established12, 13.
In this study, we assess the expression of all PTPs14 in DFs of
patients with dcSSc, in whom the occurrence of fibrosis is gen-
erally early and rapidly progressive, finding that PTP4A1 is
overexpressed in dermal SSc fibroblasts. PTP4A1 belongs to a
sub-class of three prenylated PTP (PTP4A1/2/3), which promote
growth and migration of tumor cells through mechanisms that
are not understood but probably include regulation of growth
factor signaling. The three enzymes are highly homologous to
each other, and, although they display different tissue-expression
pattern and different substrate specificity in vitro, it is unclear
whether they have different functions within the same cell
types15–17. The PTP4A sub-class of PTPs has very low activity
in vitro and robust substrates have not been reported for these
enzymes. Some of the functions of these enzymes are probably
exerted through protein–protein interaction. Indeed, PTP4A1
interacts with, and activates, the p115 Rho GTPase-activating
protein (RhoGAP)18. All three PTP4A enzymes have also been
identified as important enhancers of intracellular magnesium
levels, through their physical interaction with the CNNM family
of transmembrane magnesium channels19, 20.
Here, we show that PTP4A1 promotes TGFβ signaling in
human DFs and exacerbates experimental fibrosis in mice. In
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Fig. 1 PTP4A1 is overexpressed in SSc DFs. aMean± SEM of PTP4A1mRNA expression measured in DF lines from 13 healthy donors or patients with SSc. b
Mean± SEM of densitometric scan expression plus representative immunoblotting for PTP4A1/2 (upper bands) normalized to αtubulin (lower bands) in
five healthy and four SSc DF lines. Images are from distinct membranes. c PTP4A1/2 (green signal) and αSMA (red signal) IF in skin sections from healthy
or SSc diffuse early, diffuse late, and limited donors with Hoechst nuclear staining (blue signal). PTP4A1/2-αSMA co-localization signal appears orange in
the images. Right panels show magnified area from yellow squares in left panels. d, eMean± SEM of PTP4A1/2 fluorescence densitometry signal in αSMA
positive skin cells from two cohorts: the first one d including six healthy or five SSc diffuse early, six diffuse late and six limited donors; the second one e
including five healthy or five SSc early and five late donors. Mann–Whitney test. Scale bars, 50 μm
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human primary fibroblasts, we show that PTP4A1 sustains
extracellular regulated kinase (ERK)-dependent expression of the
important TGFβ mediator mothers against decapentaplegic
homolog 3 (SMAD3). In cells with PTP4A1 knockdown, reduced
SMAD3 expression and ERK activation correlates with reduced
SRC half-life and overall activity. We propose a molecular
mechanism in which PTP4A1 binds directly to SRC and protects
it from excessive degradation and functional inhibition. Intrigu-
ingly, PTP4A2 also promotes TGFβ signaling in human fibro-
blasts, but only minimally affects the activation of the
SRC–ERK–SMAD3 pathway. Thus, we also provide initial evi-
dence of target and functional selectivity between members of the
PTP4A sub-class co-expressed in a specific cell type.
Results
PTP4A1 is overexpressed in SSc DFs. We first assessed the
mRNA levels of all PTPs (109 genes) in four DF lines from patients
with diffuse SSc (dcSScDF) and found that 18 PTPs—belonging to
all PTP subclasses—displayed mRNA levels comparable to or
higher than the housekeeping DNA-directed RNA polymerase II
subunit RPB1 (POLR2A) gene (Supplementary Fig. 1). Next, we
compared the mRNA expression of these 18 PTPs in the four
dcSScDF and in five DF lines from normal human subjects
(NHDF). We found that the mRNAs encoding for PTP4A1 and
PTP4A2 were highly expressed in both NHDF and dcSScDF.
However, PTP4A1 displayed up to five times overexpression in
dcSScDF vs. NHDF fibroblasts, while no difference in PTP4A2
expression was detected between the two groups. PTP4A1 and
PTP4A2 are close homologs (87% identity in primary structure)
and are both overexpressed in tumors and tumor metastasis15, 17.
We thus extended the study of PTP4A1 and PTP4A2 to nine
additional dcSScDF and eight NHDF lines. In aggregate, PTP4A1
displayed two times overexpression in dcSScDF lines derived from
13 SSc patients, when compared with 13 NHDF lines, while no
differences were found in PTP4A2 levels (Fig. 1a). We next assessed
the expression of PTP4A1 and PTP4A2, at the protein level, in DF
lysates. Owing to the lack of an antibody that displays specificity for
PTP4A1 vs. PTP4A2, we distinguished the two proteins on dena-
turing polyacrylamide gels, since PTP4A2 resolves at a slightly
lower molecular weight than PTP4A1. As shown in Fig. 1b, we
found significantly increased expression of PTP4A1 but not
PTP4A2 in dcSScDF compared to NHDF lines.
To confirm that PTP4A1 is overexpressed in affected SSc skin
DFs, we performed immunofluorescence (IF) assessment of
PTP4A1 and PTP4A2 expression in dermal αSMA-positive
myofibroblasts, comparing biopsies from patients with early or late
dcSSc and limited SSc with biopsies from healthy controls. As
shown in Fig. 1c and d, myofibroblasts in the dermis of American
patients with early dcSSc (< 3 years from first non-Raynaud
manifestation) displayed a significantly increased PTP4A1/
PTP4A2 signal when compared to those from late dcSSc (> 3
years from first non-Raynaud manifestation), limited SSc and
normal controls. To confirm our observations we analyzed biopsies
from a second cohort of 10 early dcSSc patients and 5 healthy
donors from the Italian population (Fig. 1e and Supplementary
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Fig. 2 Silencing of PTP4A1 downregulates pro-fibrotic genes in NHDF. a Agarose gel with RT-PCR of PTP4A1 mRNA from NHDF lines treated with control
ASO (left lane) or with PTP4A1 ASO (right lane). b The heat map shows gene expression levels of three different NHDF lines (L1–3) treated with control
ASO or PTP4A1 ASO. NGS was performed in triplicate for each NHDF line. c List of human pro-fibrotic genes downregulated in PTP4A1 KD NHDF lines,
after DESeq analysis. d, e Left graphs show mean± SEM of SMAD3 and ACTA2 mRNA expression measured in six different NHDF lines treated with
PTP4A1 ASO and normalized to same lines treated with control ASO. Right graphs show mean± SEM of densitometric scan expression plus representative
immunoblotting for SMAD3 and αSMA (upper bands) normalized to GAPDH (lower bands) in six different NHDF lines treated with control ASO or PTP4A1
ASO. Wilcoxon test (d, e left) or Mann–Whitney test (d, e right)
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Fig. 2A). In this Italian cohort, we confirmed the overexpression of
PTP4A1/PTP4A2 in dermal myofibroblasts of dcSSc biopsies when
compared with healthy biopsies. Furthermore, myofibroblasts from
the five biopsies collected < 3 year from first non-Raynaud
manifestation showed increased expression of PTP4A1/PTP4A2
when compared to biopsies collected > 3 year from first non-
Raynaud manifestation. We conclude that PTP4A1 is significantly
overexpressed in DFs of patients with dcSSc.
Since TGFβ is considered a key cytokine activating the pro-
fibrotic program in dcSSc DFs, we examined whether PTP4A1
expression is upregulated in DFs in response to TGFβ stimula-
tion. As shown in Supplementary Fig. 2B, TGFβ stimulation of
NHDF-induced overexpression of PTP4A1, but not PTP4A2,
suggesting that increased TGFβ signaling might underlie the
selective overexpression of PTP4A1 in SSc fibroblasts.
Silencing of PTP4A1 downregulates profibrotic genes in
NHDF. To understand the role of PTP4A1 in DFs we optimized
silencing of PTP4A1 in NHDF, by using a cell-permeable anti-
sense morpholino oligonucleotide (ASO)21, 22. ASO treatment
enabled nearly complete knockdown of PTP4A1 (Fig. 2a). Next,
using next-generation sequencing (NGS), we determined the
transcriptional profile of three NHDF lines treated with PTP4A1
ASO compared to the same lines treated with a control non-
targeting ASO (Cntrl ASO). After differential expression calcu-
lation, 1886 genes displayed a log2 fold change > 0.5 in expression
and an adjusted p-value< 0.01 using Benjamini–Hochberg
method in NHDF subjected to silencing of PTP4A1. Differentially
expressed genes between PTP4A1 ASO-treated NHDF and Cntrl
ASO-treated NHDF are represented as a heat map in Fig. 2b.
Moreover, we analyzed molecular functions, biological processes,
and cellular compartments of differentially expressed genes using
the GO-Elite software23. We found that extracellular matrix
organization and cell proliferation pathways were downregulated
in PTP4A1-silenced NHDF (Supplementary Fig. 3). A subsequent
pairwise comparison of PTP4A1 ASO-treated NHDF vs. Cntrl
ASO-treated NHDF using the DESeq software24 showed that
several genes involved in human fibrosis were significantly
downregulated in PTP4A1-silenced NHDF, including genes
encoding collagen chains (COL1A2 and COL3A1) and αSMA
(ACTA2) (Fig. 2c). We also noticed that PTP4A1 knockdown
resulted in a 1.3-fold decrease in the mRNA expression of
SMAD3, which encodes for a key mediator of pro-fibrotic TFGβ
signaling25. The downregulation of both ACTA2 and SMAD3 was
further confirmed at the mRNA and protein levels in six addi-
tional NHDF lines, subjected to ASO-mediated silencing of
PTP4A1 (Fig. 2d, e). These results point to a possible role of
PTP4A1 in dermal-fibroblast-mediated skin fibrosis. Further-
more, the downregulation of SMAD3 expression in PTP4A1-
silenced NDHF also suggests a possible role of PTP4A1 in
modulating pro-fibrotic TGFβ signaling in DFs.
PTP4A1 and PTP4A2 promote TGFβ signaling in fibroblasts.
In order to evaluate the effect of PTP4A1 on TGFβ signaling in
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DFs, we stimulated with TGFβ1 both PTP4A1 ASO-treated
NHDF and Cntrl ASO-treated NHDF. We found a significant
reduction in basal and/or TGFβ-stimulated expression of
COL1A1, COL1A2, ACTA2, CTGF as well as collagen secretion in
PTP4A1-silenced NHDF (Fig. 3a–c and Supplementary Fig. 4).
Since PTP4A2 is highly homologous to PTP4A1 and is expressed
at comparable levels in DFs, we assessed whether the two phos-
phatases play similar roles on TGFβ signaling in NHDF lines.
NHDF were treated with Cntrl ASO or ASO designed to silence
PTP4A2 (PTP4A2 ASO). The PTP4A2 ASO enabled nearly
complete knockdown of PTP4A2 (Supplementary Fig. 5A).
Similar to PTP4A1-silenced fibroblasts, in PTP4A2-silenced
fibroblasts we also found a significant reduction in basal and
TGFβ-stimulated expression of COL1A2, and in TGFβ-stimulated
expression of ACTA2 (Fig. 3d, e). However, there was no evidence
of reduction in SMAD3 expression at the mRNA and protein
levels (Fig. 3f, g).
ASOs are designed against pre-mRNA splice junctions and
have a negligible chance of off-target silencing22. Nevertheless, to
confirm that the effects of PTP4A1 ASO were specifically due to
PTP4A1 silencing, we designed a second ASO targeting a different
splicing junction on the PTP4A1 pre-mRNA (PTP4A1 ASO2),
and confirmed comparable silencing efficiency to PTP4A1 ASO
(Supplementary Fig. 5A). Supplementary Fig. 5B shows that
knockdown of all ASOs in NHDF was confirmed at protein level.
Next, we incubated NHDF lines with Cntrl ASO or PTP4A1
ASO2. Similar to what observed in PTP4A1 ASO-treated NDHF
lines, PTP4A1 ASO2-treated NHDF lines displayed reduced
SMAD3 expression (Supplementary Fig. 5C) and a significant
reduction in basal and TGFβ-stimulated COL1A2 expression
(Supplementary Fig. 5D).
Since lung fibrosis is a frequent and potential life threatening
complication of SSc, we sought to determine whether promotion
of TGFβ signaling is a conserved function of PTP4A1 between
dermal and lung fibroblasts. Thus, we incubated lung fibroblast
lines from healthy donors (NHLF) with Cntrl or PTP4A1 ASO.
PTP4A1 silencing in NHLF lines (Supplementary Fig. 6A)
resulted in reduced basal and TGFβ-stimulated expression of
COL1A2 and significantly decreased SMAD3 expression (Supple-
mentary Fig. 6B–D), similar to those observed in NHDF lines.
We conclude that both PTP4A1 and PTP4A2 promote TGFβ
pro-fibrotic signaling in human dermal and lung fibroblasts.
However, the lack of redundancy between the two phosphatases
and the selective promotion of SMAD3 expression by
PTP4A1 suggest that PTP4A1 and PTP4A2 modulate fibroblast
TGFβ signaling through non-overlapping mechanisms of action.
PTP4A1 and PTP4A2 knockout (KO) protects mice from
dermal fibrosis. In order to understand whether PTP4A1 plays a
role in fibrosis in vivo, we generated a mouse strain carrying a
global deletion of PTP4A1. By analyzing more than 500 pups
produced by PTP4A1 heterozygous mating, we found that the
distribution of wild-type (WT) and mutant alleles did not exactly
match the expected Mendelian ratios. Although a significantly
reduced number of homozygous global PTP4A1 KO mice were
identified in the offspring, these PTP4A1 KOmice displayed normal
fertility and no clinically evident pathology was observed in follow-
up to the age of 24 months. Since both PTP4A1 and PTP4A2
promote pro-fibrotic TGFβ signaling in fibroblasts, we also sought
to generate PTP4A1/PTP4A2 double KO mice by crossing the
PTP4A1 heterozygous mice with the PTP4A2 KO mice described
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previously26. Unfortunately, deletion of both PTP4A1 and PTP4A2
is embryonic lethal (data not shown). However, we were able to
obtain PTP4A1 KO/PTP4A2 heterozygous (Het) mice. We then
subjected WT, PTP4A1 KO or PTP4A1 KO/PTP4A2 Het mice to
bleomycin-induced dermal fibrosis, an experimental model that is
often used in the study of both early inflammatory and fibrotic
stages of SSc27. In bleomycin-treated PTP4A1 KO compared to WT
mice, there was a significant reduction of dermal thickness, skin
collagen concentration, and ACTA2 mRNA expression. Further-
more, the phenotype of protection from fibrosis was even more
marked in PTP4A1 KO/PTP4A2 Het mice (Fig. 4a–d). To assess
whether the pro-fibrotic effect of PTP4A1 in vivo is mediated by
fibroblasts, we took advantage of a mouse model carrying a floxed
allele of PTP4A110 to generate mice carrying tamoxifen-inducible
deletion of PTP4A1 in COL1A1-expressing cells. As shown in
Fig. 4e–i Cre+ mice, subjected to postnatal tamoxifen treatment,
displayed almost complete deletion of PTP4A1 in DFs, and, con-
sistent with our observations in constitutive global PTP4A1 KO
mice, they were markedly protected from bleomycin-induced skin
fibrosis. We conclude that PTP4A1 and PTP4A2 promote skin
fibrosis in vivo.
PTP4A1 promotes TGFβ signaling through ERK–SMAD3
pathway. We next sought to understand the mechanism of action
of PTP4A1 in modulation of NHDF TGFβ signaling. We first
assessed whether promotion of SMAD3 expression by PTP4A1
results in enhanced SMAD3 occupancy on TGFβ-dependent pro-
fibrotic genes. Phospho-SMAD3 (S423/S425) chromatin immu-
noprecipitation (CHIP) in NHDF treated with PTP4A1 ASO
showed significantly reduced TGFβ-induced SMAD3 occupancy
on the COL1A2 promoter compared with Cntrl ASO-treated cells
(Fig. 5a). IF assessment of SMAD3 localization, in the same cells,
confirmed overall reduced levels of SMAD3 (Supplementary
Fig. 7A). In addition, we also found a reduced nuclear-
cytoplasmic SMAD3 ratio in TGFβ-stimulated PTP4A1 ASO-
treated NHDF lines when compared with Cntrl ASO-treated
NHDF lines (Fig. 5b and Supplementary Fig. 7A). These data
suggest that reduced TGFβ-induced SMAD3 occupancy of target
loci in PTP4A1-silenced fibroblasts is due to a combination of
decreased expression of SMAD3 and diminished TGFβ-induced
nuclear translocation or retention. Phosphorylation of SMAD3
on S423/S425 is necessary for its cytoplasmic-nuclear transloca-
tion25. However, NHDF lines, subjected to PTP4A1 silencing, did
not display any significant difference in TGFβ-induced phos-
phorylation of SMAD3 S423/425 (Supplementary Fig. 7B).
SMAD3 expression has been reported to be dependent on ERK1/
2 mitogen-activated protein kinase (MAPK) pathway activation
in human alveolar type II epithelial adenocarcinoma cell line
(A549)28. In fibroblasts, phosphorylation of SMAD3 by ERK1/2
on S204 also promotes its COL1A2-activating function29.
Reportedly, all three prenylated PTPs promote activation of
SMAD3 mRNAc
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Fig. 5 PTP4A1 influences TGFβ pro-fibrotic signaling through SMAD3. a Mean± SEM of COL1A2 promoter expression in six different NHDF lines treated
with PTP4A1 ASO, stimulated with TGFβ1 and normalized to the same lines treated with control ASO. pSMAD3 antibody was used to perform the ChIP. b
Mean± SEM of the ratio between SMAD3 nuclear and cytoplasmatic fluorescence densitometry in three cell lines treated with control ASO and PTP4A1
ASO and then stimulated with TGFβ1. cMean± SEM of SMAD3mRNA expression measured by qPCR in three NHDF lines treated with 50 μm SCH772984
ERK inhibitor and normalized to the same lines treated with DMSO. d Mean± SEM of densitometric scan expression plus representative immunoblotting
for pERK1/2 (T202/Y204) (upper bands) normalized to ERK2 (lower bands) in four different NHDF lines treated with control ASO, PTP4A1 ASO (left
graph) or PTP4A2 ASO (right graph, three different NHDF lines). Images are from different lanes on the same membrane. e Left graph shows mean± SEM
of relative ratio of firefly/Renilla luciferase signal of HEK 293T cells co-transfected with human PTP4A1 WT or PTP4A2 WT-encoding HA-tag pCDNA4
vectors together with a firefly luciferase SMAD reporter and a control luciferase Renilla vector. Cells were stimulated with TGFβ1. Graph is representative of
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ERK1/2 in cancer cells30. Thus, we hypothesized that reduced
basal activation of ERK1/2 might explain the reduced basal
expression and TGFβ-induced nuclear translocation of SMAD3
in PTP4A1-silenced NHDF lines. In order to test this hypothesis,
we first assessed whether SMAD3 expression and its TGFβ-
induced nuclear translocation are ERK-dependent in NHDF lines.
Figure 5c and Supplementary Fig. 8A show that treatment of
NHDF with the selective ERK1/2 inhibitor SCH77298431 resulted
in significantly reduced SMAD3 mRNA level and reduced TGFβ-
induced SMAD3 nuclear translocation, when compared to
DMSO-treated cells. Next, we assessed whether PTP4A1 and
PTP4A2 promote ERK1/2 activity in NHDF lines. Figure 5d
shows that NHDF lines, treated with PTP4A1 ASO, displayed
significantly reduced basal phosphorylation of ERK1/2 on T202/
Y204, when compared with Cntrl ASO-treated NDHF lines.
However, consistent with the observed lack of differences in
SMAD3 expression in PTP4A2 ASO-treated NHDF lines,
PTP4A2 silencing only caused a small non-significant trend in
reduced ERK1/2 phosphorylation. Consistent with the hypothesis
that PTP4A1 promotes SMAD3 cytosolic-nuclear shuttling via
ERK activation, we did not observe any evidence of altered TGFβ-
induced nuclear translocation of SMAD3 in PTP4A2-silenced
NHDF lines (Supplementary Fig. 8B). Overall, our data suggest
that promotion of TGFβ signaling by PTP4A1 in NHDF is at least
in part mediated by enhanced basal activation of ERK1/2, which
results in enhanced expression of SMAD3, and primes it for
enhanced TGFβ-induced nuclear translocation. Consistent with
this hypothesis, DF lines from SSc patients displayed significant
increased ERK1/2 activity when compared to NHDF (Supple-
mentary Fig. 8C). Intriguingly, this function of PTP4A1 is not or
only minimally shared by PTP4A2 in NHDF lines, despite the
high homology between the two phosphatases and the fact that
both PTP4A1 and PTP4A2 promote TGFβ signaling in NHDF
lines. To gather further support to the observed different function
exerted by PTP4A1 vs. PTP4A2 in TGFβ signaling, we assessed
whether overexpression of PTP4A1 enhances the activation of a
SMAD-dependent luciferase reporter in HEK 293T cells. This
reporter assay has been described to be ERK-dependent28 and we
confirmed that it could be inhibited by cell treatments with
SCH772984 (Supplementary Fig. 8D). Thus, we co-transfected
HEK 293T cells with the SMAD luciferase reporter and human
pCDNA4-encoded PTP4A1 or PTP4A2. After TGFβ stimulation,
luciferase activity was enhanced 2.7 times in cells expressing
PTP4A1, but only 1.6 times in cells expressing PTP4A2, despite
the transfected cells displayed equal expression levels of the two
phosphatases (Fig. 5e).
PTP4A1 and PTP4A3 have been reported to promote
activation of Rho and of its major effector Rho-associated protein
kinase (ROCK) in cancer cells32. ROCK activity is increased in
pulmonary fibrosis33. ROCK also promotes pro-fibrotic TGFβ
signaling in DF and inhibition of ROCK protects bleomycin-
treated mice from the development of dermal fibrosis34. Thus, we
assessed whether increased activation of ROCK contributes to the
PTP4A1-mediated enhancement of TGFβ signaling in NHDF
lines. As shown in Fig. 5f, while PTP4A1 silencing had no effect
on ROCK activity in NHDF lines, PTP4A2 silencing led to a
pPLCγ (Y783)f
p= 0.0382
_130 kDa
_
35 kDa
pSRC (Y527)
p= 0.0239
_70 kDa
pSRC (Y416)e
p= 0.0336
_70 kDa
SRC mRNASRC proteind _
70 kDa
_35 kDa
SRC mRNApMEK1/2 (S217/221)a
p= 0.0087
Cn
trl
 A
SO
PT
P4
A1
 A
SO
Cn
trl
 A
SO
PT
P4
A2
 A
SO
Cn
trl
 A
SO
PT
P4
A2
 A
SO
Cn
trl
 A
SO
PT
P4
A1
 A
SO
Cn
trl
 A
SO
PT
P4
A1
 A
SO
Cn
trl
 A
SO
PT
P4
A1
 A
SO
_
55 kDa
1.5
2.0
1.5
1.5
1.0
1.0
0.5
0.5
0.0
2.0
1.5
1.0
0.5
0.00.0
1.5
1.0
0.5
0.0
1.5
1.0
0.5
0.0
R
el
at
iv
e 
ph
os
ph
or
yl
at
io
n 
le
ve
ls
1.0
0.5
0.0
pRAF (S259)
b
p= 0.0489
_
70 kDa
_
35 kDa
SRC proteinc
p= 0.0286
_
70 kDa
_
35 kDa
4 1.5 2.0
1.5
1.0
0.5
0.0
1.0
0.5
0.0
3
2
1
0
R
el
at
iv
e 
ph
os
ph
or
yl
at
io
n 
le
ve
ls
R
el
at
iv
e 
ph
os
ph
or
yl
at
io
n 
le
ve
ls
R
el
at
iv
e 
ph
os
ph
or
yl
at
io
n 
le
ve
ls
R
el
at
iv
e 
ph
os
ph
or
yl
at
io
n 
le
ve
ls
R
el
at
iv
e 
ex
pr
es
si
on
R
el
at
iv
e 
ex
pr
es
si
on
R
el
at
iv
e 
ex
pr
es
si
on
Cn
trl
 A
SO
PT
P4
A1
 A
SO
Cn
trl
 A
SO
PT
P4
A1
 A
SO
Cn
trl
 A
SO
PT
P4
A1
 A
SO
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dramatic inhibition of ROCK activity in TGFβ-stimulated NHDF
lines.
Since PTP4A1 inhibits CNNM function leading to increased
intracellular Mg levels in HeLa, COS7, and HEK 293 cells35, we
also assessed whether regulation of CNNM channel physiology
contributes to the action of PTP4A1 in TGFβ signaling. Since
HEK 293 cells almost exclusively express CNNM4 channels35, we
examined the effect of knockdown of CNNM4 in HEK 293 cells
on SMAD reporter activation by TGFβ. As shown in Supple-
mentary Fig. 9A, knockdown of CNNM4 did not affect TGFβ-
mediated reporter activation, suggesting that the mechanism of
action of PTP4A1 in TGFβ signaling is unlikely mediated by
decreased CNNM4 function. In line with this model, reporter
assays carried out in Mg-free media also showed that while Mg
was necessary for full reporter activation, reporter enhancement
by PTP4A1 was unaffected by Mg deficiency (Supplementary
Fig. 9B). Taken together, our data suggest that promotion of
TGFβ-induced pro-fibrotic gene expression by PTP4A1 occurs
through basal enhancement of ERK activation, which in turn
boosts transcription and nuclear translocation/retention of
SMAD3, resulting in promotion of canonical TGFβ signaling.
Additionally, our data suggest that PTP4A1 and PTP4A2 regulate
different aspects of TGFβ signaling in NHDF signaling.
PTP4A1 enhances SRC half-life in NHDF lines. To understand
how PTP4A1 promotes activation of ERK1/2 in NHDF lines, we
first assessed whether PTP4A1 affects the activation of upstream
MAPK kinases and MAPK kinase kinases (MAPKK and
MAPKKK) in the ERK pathway36. We found that NDHF lines
subjected to PTP4A1 silencing displayed significantly reduced
phosphorylation of the MAPKK mitogen-activated protein kinase
kinases 1/2 (MEK1/2) on S217/S221 and of the RAF proto-
oncogene serine/threonine-protein kinase (RAF) MAPKKK on
S259 (Fig. 6a, b). SRC is a major effector of RAF activation
through activation of RAS37. In cancer cell lines, two groups have
separately reported that PTP4A1 promotes SRC autopho-
sphorylation on Y416 and SRC protein expression levels,
respectively38, 39. However, the molecular basis of SRC regulation
by PTP4A1 remains unclear and the two above-mentioned
observations are hard to reconcile since autophosphorylation of
SRC Y416 induces its degradation through Cul5-mediated
ubiquitination40, 41. In order to evaluate whether PTP4A1 pro-
motes the activation of the ERK pathway in NHDF lines through
an action on SRC, we assessed the expression and the activity of
SRC in NHDF lines subjected to PTP4A1 silencing. Figure 6c and
d shows that PTP4A1 silencing in NHDF lines resulted in a sig-
nificant reduction of SRC protein expression, but not of SRC
mRNA levels, while PTP4A2 silencing in the same cells did not
affect SRC expression at all. Next, we examined SRC phosphor-
ylation levels on Y416 and Y527—the latter is an inhibitory site
that is specifically phosphorylated by the C-terminal SRC kinase
(CSK)—in NHDF lines subjected to PTP4A1 silencing. We found
significantly increased phosphorylation of SRC on both Y416 and
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Fig. 7 PTP4A1 inhibits the basal autophosphorylation of SRC. a Mean± SEM of relative ratio of firefly/Renilla luciferase signal of HEK 293T cells
co-transfected with human HA-tagged PTP4A1 WT or PTP4A1 C104S (phosphatase dead)-encoding pCDNA4 vector together with a firefly luciferase
SMAD reporter and a control Renilla luciferase vector. Cells were stimulated with TGFβ1. Graph is representative of three independent experiments.
b–d Mean± SEM of SMAD3 or SRC mRNA expression or densitometric scan relative expression plus representative immunoblotting for SMAD3, SRC,
pERK1/2 (T202/Y204) (upper bands) normalized to GAPDH or αtubulin (lower bands) in three different NHDF lines treated with control ASO or PTP4A1
ASO3. e Mean± SEM of densitometric scan expression plus representative immunoblotting for pSRC (Y416) (upper bands) normalized to SRC (lower
bands) in three different in vitro SRC kinase assay followed by incubation with PTP4A1/PTP4A2. f Densitometric scan expression plus representative
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Y527 in PTP4A1 ASO-treated when compared to Cntrl ASO-
treated fibroblasts (Fig. 6e). In order to evaluate SRC activity in
cells subjected to PTP4A1 silencing, we assessed phosphorylation
of Y783 of phospholipase C gamma 1 (PLCγ)—a specific SRC
phosphorylation site42. We found that PTP4A1 ASO-treated cells
incubated with PTP4A1 ASO displayed reduced PLCγ-Y783
phosphorylation (Fig. 6f). We conclude that PTP4A1 promotes
SRC half-life through decreased basal SRC autophosphorylation
on Y416. We hypothesize that in cells expressing PTP4A1 the
combination of sustained SRC expression and decreased phos-
phorylation on Y527 results in enhanced SRC basal activity,
which in turn enhances SMAD3 expression and nuclear trans-
location via ERK activation. In line with this hypothesis, we
observed that DF lines from SSc patients displayed significant
increased SRC protein level when compared to NHDF (Supple-
mentary Fig. 10A). Moreover, treatment of NHDF with the
selective SRC inhibitor SU6656 resulted in significantly reduced
TGFβ-induced SMAD3 nuclear translocation, when compared to
DMSO-treated cells (Supplementary Fig. 10B).
We next sought to understand how PTP4A1 inhibits
phosphorylation of SRC on Y416. Since PTP4A1 is a tyrosine
phosphatase, an obvious scenario is that PTP4A1 directly
dephosphorylates SRC Y416. To test this hypothesis, we first
determined whether the catalytic activity of PTP4A1 is necessary
for PTP4A1-mediated promotion of TGFβ signaling by measur-
ing the SMAD luciferase reporter activity in HEK 293T
expressing HA-tagged human PTP4A1 or its catalytically dead
C104S mutant. These experiments showed that expression of
PTP4A1 C104S leads to enhanced TGFβ-induced luciferase
activity comparable to the expression of the WT enzyme,
suggesting that the phosphatase activity of PTP4A1 is dispensable
for its TGFβ signaling promoting action (Fig. 7a). In order to
define whether in NHDF lines the phosphatase activity of
PTP4A1 is dispensable for its effect on SRC half-life and activity,
we designed an ASO for in-frame deletion of PTP4A1 exon 4 (aa
110–135), thus eliminating R110, which is critical for enzyme
catalysis, without altering all the other active site residues
(Supplementary Fig. 11A). Indeed, we showed that recombinant
Δ110-135PTP4A1 (ΔPTP4A1) lacks enzymatic activity in vitro
(Supplementary Fig. 11B). The short alpha helix-turn-alpha helix
loop encoded by exon 4 is almost completely conserved between
PTP4A1 and PTP4A2, thus is unlikely to contribute significantly
to the regulation of SRC by PTP4A1. In PTP4A1 ASO3-treated
cells, we did not find any significant reduction in SMAD3 or SRC
expression (Fig. 7b, c) as well as basal phosphorylation of ERK on
T202/Y204 (Fig. 7d), thus indicating that regulation of SRC
activity and expression by PTP4A1 do not require PTP4A1
catalytic activity.
Next, we sought to further understand the action of PTP4A1
on SRC phosphorylation through in vitro molecular assays. We
first assessed whether recombinant PTP4A1 is able to depho-
sphorylate SRC subjected to in vitro autophosphorylation on
Y416. Figure 7e shows that neither recombinant PTP4A1 or
PTP4A2 dephosphorylated SRC Y416. We conclude that, in line
with the above-mentioned observations, PTP4A1 is unlikely to
directly dephosphorylate SRC on Y416 in NHDF. In the same
in vitro assays, we noticed that recombinant PTP4A1 and
PTP4A2 formed a physical complex with active SRC, which was
persistent after several washes (Fig. 7f and Supplementary
Fig. 12A). Complex formation was much more prominent for
PTP4A1 than PTP4A2, suggesting that PTP4A1 is capable of a
physical interaction with SRC. Importantly, ΔPTP4A1, which
retains PTP4A1 function but not its enzymatic activity, also
retains PTP4A1 ability to co-precipitate with SRC (Supplemen-
tary Fig. 12B). To confirm this observation in a cellular context,
we immunoprecipitated both HA-tagged PTP4A1 and PTP4A2
or SRC from lysates of HEK 293T transfected with HA-tagged
catalytically active human PTP4A1 or PTP4A2 or catalytically
inactive human PTP4A1-C104S or PTP4A2-C101S. In these
experiments, we confirmed that PTP4A1 co-precipitates with
SRC much more efficiently than PTP4A2 (Supplementary
Fig. 12C, D). The observed physical interaction between PTP4A1
and SRC, coupled with lack of direct dephosphorylation of
PTP4A1 by SRC, suggests that regulation of SRC autopho-
sphorylation by PTP4A1 might rather occur through a “chaper-
one-like” protein–protein interaction mechanism. To test this
hypothesis, we subjected recombinant SRC to autophosphoryla-
tion in an in vitro kinase assay in the presence of recombinant
PTP4A1 or PTP4A2. In this assay, only PTP4A1 significantly
inhibited SRC autophosphorylation on tyrosine 416 (Fig. 7g).
Thus, binding of PTP4A1 to SRC correlates with inhibition of the
basal auto-phosphorylation of SRC, suggesting that PTP4A1 is
critical to avoid excessive autophosphorylation of SRC, in the
absence of acute cell stimuli. A wide range of subcellular
localizations, including membranes, cytosol, and nucleus, has
been reported for the PTP4A phosphatases15. Prenylation is
believed to increase their localization at the plasma membrane43,
which could theoretically enhance their access to the active pool
of SRC. However, differences in the behavior of PTP4A1 and
PTP4A2, in the above-mentioned cellular and in vitro SRC assays,
suggest that prenylation is not critical for recruitment of PTP4A1
to SRC, and presumably, for the regulation of TGFβ signaling by
PTP4A1. This consideration is experimentally supported by the
fact that we did not find any difference between the ability of WT
PTP4A1 and its 1–169 mutant, which lacks all prenylation sites30,
to enhance TGFβ-induced SMAD reporter luciferase activity
(Supplementary Fig. 13).
Discussion
Differentiation into αSMA-expressing myofibroblasts and
increased collagen deposition are considered key pro-fibrotic
alterations of fibroblast function in SSc2. TGFβ signaling is
believed to significantly contributing as a major driver of the pro-
fibrotic phenotype of SSc fibroblasts and anti-TGFβ treatments
are being tested in clinical trials with promising results5, 6.
Molecular signaling alterations in TGFβ and other signaling
pathways in SSc fibroblasts and tissues have been object of intense
investigation4, 5, 44, 45. However, with the exception of early
observations on the PTEN—phosphatidylinositol-4,5-bispho-
sphate 3-kinase pathway4, 10 and a single report on PTP1B11—the
role of PTP has remained unaddressed.
Here, we carried out an unbiased survey of PTP mRNA
expression in SSc fibroblasts and found that PTP4A1 mRNA and
protein are significantly overexpressed in SScDF lines derived
from patients in the early stage of the disease, when compared
with lines derived from patients at the later stage, patients with
limited SSc and healthy controls. Furthermore, the expression of
PTP4A1/PTP4A2 was also significantly increased in the skin of
the same patients. A few scenarios are envisioned to explain the
mechanism of PTP4A1 overexpression in SSc DFs. SSc fibroblast
lines display multiple imprinted alterations in signaling and gene
expression, including enhanced TGFβ signaling and increased
expression of TGFβ receptors46, 47. Epigenetic anomalies likely
underlie at least in part these imprinted phenotypes of SScDF
lines in culture48. It is possible that the PTP4A1 locus displays
epigenetic alterations in SScDF cells. Alternatively, or in addition,
the experimental induction of PTP4A1 by TGFβ in NHDF lines
suggests that increased levels of TGFβ in the pro-fibrotic milieu of
SSc skin, together with enhanced endogenous TGFβ sensitivity of
SSc fibroblasts, might underlie the overexpression of PTP4A1 in
early SSc skin stages and SSc fibroblasts5, 46, 47. Since early stages
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of SSc are characterized by enhanced immune-mediated inflam-
mation, it is also possible that additional cytokines/inflammatory
stimuli boost PTP4A1/PTP4A2 expression in early vs. late SSc
biopsies.
Our transcriptomic study in resting NHDF lines subjected to
silencing of PTP4A1 showed that PTP4A1 promotes in these cells
the expression of a pro-fibrotic gene signature. Importantly,
PTP4A1 appeared to critically increase the expression levels of
SMAD3, a key mediator of TGFβ signaling, leading to the
hypothesis that PTP4A1 plays a positive role in TGFβ signaling of
NHDF lines. Subsequent experiments showed that PTP4A1
indeed enhances pro-fibrotic TGFβ signaling in NHDF lines as
well as in lung fibroblasts and that deletion of PTP4A1 in vivo
exerts a protective effect against bleomycin-induced fibrosis.
PTP4A2 similarly promotes pro-fibrotic TGFβ signaling in
NHDF lines and bleomycin-induced fibrosis in vivo. These
experiments led us to define PTP4A1 and PTP4A2 as novel
promoters of TGFβ signaling, a function that they currently share
with very few additional tyrosine phosphatases12, 13. The
bleomycin-induced dermal fibrosis model is widely used for
modeling late stages of excessive accumulation of collagen and
other extracellular matrix components in scleroderma9, 27. Thus,
our data also points to a possible role for PTP4A1 and PTP4A2 in
mediating fibrosis in SSc. The fibroblast-specific expression of the
fibrotic markers that correlate with PTP4A1 expression in mice
and the phenotype of the COL1A1-Cre conditional KO mouse
strongly supports the idea that PTP4A1 promotes fibrosis
through an effect on fibroblasts. However, effects of PTP4A1
and/or PTP4A2 on additional cell types cannot be ruled out and
warrant further investigation.
We next focused on elucidating the mechanism of action of
PTP4A1 on TGFβ signaling in NHDF lines. Our data suggest a
model where PTP4A1 enhances TGFβ signaling by driving basal
expression of SMAD3 and promoting SMAD3 nuclear translo-
cation/retention. Since we find that in NHDF lines PTP4A1 is a
critical promoter of basal ERK phosphorylation and that ERK
activity controls SMAD3 expression and TGFβ-induced nuclear
translocation, we propose that PTP4A1 controls SMAD3
expression and cytosolic-nuclear shuttling through promotion of
basal ERK activity. Surprisingly, in NHDF lines PTP4A2 does not
influence SMAD3 expression or nuclear translocation and only
minimally affects ERK activity. While this observation was
unexpected based on the reports that both PTP4A1 and PTP4A2
promote ERK signaling in cancer cells, it does support the pos-
sibility that, in NHDF lines, only PTP4A1 controls TGFβ sig-
naling through the ERK pathway. Another shared function of
PTP4A1 and PTP4A2 in cancer cells is the promotion of Rho-
GAP and downstream Rho activation through an action on p115
Rho18, 32. However, in NHDF lines promotion of ROCK activity
appeared to be an exclusive function of PTP4A2, suggesting that
PTP4A1 and PTP4A2 control different pro-fibrotic signaling
pathways in NHDF lines and perhaps in vivo. The apparent lack
of functional overlap between PTP4A1 and PTP4A2 in NHDF
lines may be due to cell-specific differences in enzyme localization
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Fig. 8 PTP4A1 promotes TGFβ signaling in DFs. PTP4A1 interacts with SRC and promotes SRC half-life, which in turn enhances activation of the MAPK
pathway. Activated ERK1/2 induces transcription of SMAD3 and promotes TGFβ-driven SMAD3 nuclear translocation, which boosts pro-fibrotic TGFβ
signaling. PTP4A2, despite its high identity with PTP4A1, does not interact with SRC or affect the MAPK–SMAD3 pathway. However, it also promotes pro-
fibrotic signaling, perhaps through selective activation of the ROCK pathway. Orange continuous connectors: TGFβ signaling pathways. Black connectors:
PTP4A1/PTP4A2 functions in human DFs
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and regulation. In addition, most of the previous studies have
been carried out in growth factor-stimulated cells, where cross-
activation of different pathways, for example, between the Rho
and ERK pathway34, might blur functional differences between
the two phosphatase homologs.
An assessment of signaling upstream ERK led us to the
observation that SRC activity is decreased in NHDF lines sub-
jected to PTP4A1 silencing. This finding correlated with
decreased levels of SRC at the protein level, in PTP4A1-silenced
NHDF lines, while SRC mRNA levels remained unaffected. Thus,
we suggest a model where PTP4A1 promotes ERK signaling in
NHDF lines through enhancement of basal SRC half-life. It has
been reported that silencing of PTP4A1 in human lung cancer
cells resulted in reduced SRC half-life, though the molecular
mechanism behind the regulation of SRC by PTP4A1 was not
addressed39. Since auto-phosphorylation of SRC on the activatory
Y416 leads to Cul5-mediated ubiquitination and
degradation40, 41, one might hypothesize that PTP4A1 is an
inhibitor of SRC auto-phosphorylation. To date, only one report
has addressed the effect of PTP4A1 on SRC activity in HEK 293
cells, concluding that PTP4A1 promotes SRC Y416 phosphor-
ylation38. In our experiments, consistent with the known model
of regulation of SRC half-life, by Y416 phosphorylation, silencing
of PTP4A1 resulted in increased phosphorylation of SRC on Y416
in resting NHDF lines. In these cells, we also observed increased
phosphorylation of SRC on the inhibitory Y527. The latter phe-
nomenon might be a compensatory mechanism, triggered by
increased basal activation of SRC. Another scenario is that lack of
PTP4A1 not only directly promotes auto-phosphorylation of SRC
Y416, but also phosphorylation of SRC Y527. However, we could
not find significant difference in expression levels of CSK—the
kinase that phosphorylates SRC Y527—in NHDF treated with
PTP4A1 ASO vs. Cntrl ASO (Supplementary Fig. 14A, B).
Moreover, PTP4A1 was unable to in vitro dephosphorylate SRC
on pY527 (Supplementary Fig. 14C, CD45 is a known SRC pY572
phosphatase and was used as a control in this experiment).
Irrespective, our data suggest that PTP4A1 operates as a basal
SRC rheostat, by inhibiting SRC degradation through decreased
phosphorylation at Y416, and priming SRC for activation by
decreased phosphorylation at Y527. Importantly, silencing of
PTP4A2 did not influence SRC expression or stability, as well as
the activation of MAPKK and MAPKKK upstream ERK in
NHDF lines, further supporting the importance of SRC in the
mechanism of action of PTP4A1 in these cells.
We finally sought to clarify how PTP4A1 regulates SRC
phosphorylation on Y416. Our data suggest that inhibition of
SRC phosphorylation by PTP4A1 does not depend on PTP4A1
catalytic activity. By comparing PTP4A1 and PTP4A2 in parallel
assays, we show that SRC activation in PTP4A1-silenced NHDF
lines correlates with a selective ability of PTP4A1 to physically
interact with SRC and inhibit its auto-phosphorylation in in vitro
kinase assays. Thus, we propose that PTP4A1 inhibits basal SRC
auto-phosphorylation and degradation through a direct interac-
tion with SRC. This model is consistent with the notion that
PTP4A phosphatases display only weak activity in vitro on gen-
eral phosphatase substrates49 and agrees with reports showing
that at least two of the major functions of PTP4A1 and/or
PTP4A2—regulation of CNNM channels, and of RhoGAP
function—are based on protein–protein interaction, rather than
substrate dephosphorylation18, 35, 50. Among tyrosine phospha-
tases devoid of catalytic activity, the pseudophosphatase STYX
can operate as an ERK anchor and inhibits ERK activity51.
However, the molecular basis of ERK inhibition by STYX has not
yet been elucidated. The observation that PTP4A1 inhibits SRC
auto-phosphorylation in a catalytic activity-independent manner
resemble the mechanism of regulation of two-component
phosphohistidine-based systems by some prokaryotic bacterial
phosphatases52. The molecular details of the specific interaction
between SRC and PTP4A1 warrant further investigation. Possible
mechanisms of SRC inhibition by the PTP4A1–SRC complex
include steric inhibition of substrate accessibility and/or induc-
tion of kinase conformational changes. It also remains to be
clarified whether the interaction of SRC with PTP4A1 influences
the ability of SRC to phosphorylate its downstream substrates.
The limited SRC-preservation activity of PTP4A1 in vitro could
be sufficient to limit regulation of SRC activity and half-life by
PTP4A1 to resting cells, thus avoiding significant limitations to
SRC activation after growth factor or other SRC-dependent cell
stimuli. Alternatively, specific mechanisms might be in place to
remove PTP4A1 from SRC, after cells are subjected to specific
stimuli.
In conclusion, we showed that PTP4A1, a tyrosine phosphatase
overexpressed in DFs of patients with SSc, enhances canonical
pro-fibrotic TGFβ signaling in these cells. We propose a model
(Fig. 8) where, in resting fibroblasts, PTP4A1 directly interacts
with SRC and inhibits its basal phosphorylation on Y416, thus
limiting SRC degradation. The larger pool of available SRC, in
combination with decreased phosphorylation of SRC on inhibi-
tory Y527, promotes SMAD3 expression through the ERK
pathway. Increased SMAD3 expression and perhaps SMAD3
phosphorylation by ERK in turn increase responsiveness of
NHDF to TGFβ stimulation. Our results are consistent with
previous observations that SRC activity is essential for TGFβ
responsiveness of DFs53.
By clarifying the relationship between SRC and PTP4A1 and
showing that the functional overlap between PTP4A1 and
PTP4A2 is less extensive than expected, our findings significantly
contributes to clarification of the biology of the elusive PTP4A
subclass of PTPs. Our study also suggests that interfering with the
interaction between PTP4A1 and SRC might represent a ther-
apeutic strategy in fibrotic diseases where TGFβ is believed to play
a pathogenic role.
Methods
Antibodies and other reagents. The mouse anti-PTP4A1/2 (clone 42) antibody
was purchased from EMD Millipore (Billerica, MA). The rabbit anti-SMAD3
(catalog number 9513), rabbit anti-pSMAD3 (S423/S425, clone C25A9), rabbit
anti-pERK1/2 (T202/Y204, catalog number 9101), rabbit anti-HA (clone C29F4),
rabbit anti-MEK1/2 (catalog number 9122), rabbit anti-pMEK1/2 (S217/221, cat-
alog number 9121), rabbit anti-pRAF (S259, catalog number 9421), rabbit
anti-pPLCγ (Y783, catalog number 2821), rabbit anti-SRC (catalog number 2108),
mouse anti-SRC (clone L4A1), rabbit anti-pSRC (Y416, catalog number 2101),
rabbit anti-pSRC (Y527, catalog number 2105), and rabbit anti-GAPDH (clone
14C10) antibodies were purchased from Cell Signaling Technology (Danvers, MA).
The mouse anti-αSMA (clone 1A4), Cy3-conjugated mouse anti-αSMA (clone
1A4), and mouse anti-αTubulin (clone DM1A) antibodies were purchased from
Sigma-Aldrich (St. Louis, MO). The rabbit anti-αSMA antibody (catalog number
5694) was purchased from Abcam (Cambridge, MA). Secondary antibodies for
western blotting and IF were purchased from GE Healthcare Life Sciences
(Buckinghamshire, UK) and eBioscience (San Diego, CA). Antisense oligonu-
cleotides were from Gene Tools LLC (Philomath, OR). Transforming growth factor
beta 1 (TGFβ1) was purchased from eBioscience (San Diego, CA). Bleomycin
sulfate, the SB505124 TGFβ inhibitor, the SU6656 SRC inhibitor, and the
SCH772984 ERK inhibitor were purchased from Selleck Chemicals (Houston, TX).
Recombinant GST-tagged SRC (rSRC), recombinant CD45 (rCD45), recombinant
HA-tagged PTP4A1 (rPTP4A1), or PTP4A2 (rPTP4A2) were purchased from
R&D Systems (Minneapolis, MN). Recombinant GST-tagged CSK (rCSK) was
purchased from EMD Millipore. Unless specified, chemicals and all other reagents
were purchased from Sigma-Aldrich.
SSc and healthy skin samples. SSc and healthy skin biopsies and DFs lines were
obtained from the Thomas Jefferson University (TJU IRB #06F.186), the UC San
Diego Division of Rheumatology (UC San Diego IRB #140485), the UCSF Scler-
oderma Center (UCSF IRB #15-16463), and the ASL Avezzano Sulmona L’Aquila
(protocol number #0214409/16). Healthy skin samples were also obtained through
the NDRI tissue bank (Philadelphia, PA). Lung fibroblast cell lines were obtained
from ATCC (Manassas, VA) and Lonza (Basel, Switzerland). All patients met the
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criteria for SSc1, and fulfilled the criteria for dcSSc or lcSSc. dcSSc patients recruited
< 3 years from first non-Raynaud manifestation were classified as early dcSSc and
patients recruited > 3 years from first non-Raynaud manifestation were classified as
late dcSSc15. The cohorts included 40 male and female Caucasian and African
American patients with SSc, or 12 female Caucasian healthy subjects, aged between
18 and 80 years old (see Supplementary Table 1 for more details about the SSc
cohorts). All patients and controls signed a consent form approved by the local
institutional review boards (TJU IRB #06F.186, UC San Diego IRB #140485,
UCSF IRB #15-16463, and ASL Avezzano Sulmona L’Aquila protocol number
#0214409/16).
DFs were cultured in complete Dulbecco’s Modified Eagle’s Medium from
Thermo Fisher Scientific (Waltham, MA) with 10% fetal bovine serum (FBS) from
Omega Scientific (Tarzana, CA), 100 units/ml of penicillin and 100 μg/ml
streptomycin from Thermo Fisher Scientific at 37 °C in a humidified 5% CO2
atmosphere. For all experiments, fibroblasts were used between passages 3 and 8,
and cells were synchronized in serum-starved media with 0.1% FBS for 24 h prior
to analysis or functional assays. None of the cell lines used were listed as a
misidentified cell line in the International Cell Line Authentication Committee
database. The absence of mycoplasma contamination was confirmed using the
MycoAlert Mycoplasma Detection Kit from Lonza.
IF analysis of human skin. Paraffin-embedded sections of human skin were
deparaffinized, rehydrated, and treated for 10 min with boiling citrate antigen-
retrieval buffer (1.9 mM citric acid, 10 mM Tris-sodium citrate, pH 6.0). Slides
were blocked with 5% goat serum for 1 h at room temperature (RT) and incubated
overnight at 4 °C with mouse anti-PTP4A1/2 antibody and rabbit anti-αSMA
(1:200 dilution in 5% bovine serum albumin (BSA)). Slides were washed and
incubated for 1 h with Alexa Fluor 488-conjugated goat anti-mouse IgG Alexa
Fluor 568-conjugated goat anti-rabbit IgG (1:500 dilution in 5% BSA). Nuclei were
stained for 10 min at RT with 5 µg/ml Hoechst 33242 from Thermo Fisher Sci-
entific. Images were obtained using a Fluoview FV10i confocal microscope or a
BX53 fluorescence microscope from Olympus (Tokyo, Japan). PTP4A1/2 fluores-
cence densitometry was assessed only in cells co-stained with αSMA in three
different fields for each slide. ImageJ software was used for signal quantification.
Mice. Animal experiments were conducted in accordance with Institutional Ani-
mal Care and Use Committee-approved protocols at Purdue University
(#1511001324) and at the La Jolla Institute for Allergy & Immunology (#AP140-
NB4). Eight-week-old female C57BL/6 mice were obtained from the Jackson
Laboratory (Bar Harbor, ME). C57BL/6 mice carrying deletion of PTP4A2
(PTP4A2 KO) have already been described26. A heterozygous gene-trapped
embryonic stem (ES) cell line (Cell No.: CC0606; Mouse strain: 129P2/OlaHsd)
containing an insertional mutation in the mouse PTP4A1 locus was purchased
from the Mutant Mouse Regional Resource Centers (MMRRC). ES cells were
injected into blastocysts from C57BL/6J mice at the Transgenic and Knock-Out
Mouse Core of the Indiana University Simon Cancer Center. Heterozygous males
resulting from successful germ-line transmission of the mutant allele were inter-
crossed with C57BL/6J females to generate F1 offspring. The PTP4A1-targeted ES
cell line was subjected to genetic confirmation assessment at MMRRC, which
included long-range PCR to confirm proper targeting, vector copy number count,
and Y chromosome verification. Reverse transcription polymerase chain reaction
(RT-PCR) assessment showed that PTP4A1 KO mice do not express PTP4A1. In
addition, RT-PCR revealed that beta-geo is not expressed as well in 12-week-old
female PTP4A1 KO mice. 8–12-week-old female PTP4A1 and PTP4A2 KO mice
used in this study were on C57BL/6:129P2 mixed genetic background. LacZ pri-
mers for beta-geo expression, 5′-GATCGCGTCACACTACGTCT-3′ (forward) and
5′-GTGGCCTGATTCATTCCCCA-3′ (reverse), were purchased from IDT.
PTP4A1fl/fl homozygous mice on C57BL/6 background have been already descri-
bed10 and were mated with C57BL/6.Cg-Tg(COL1A1-Cre/ERT2)1Crm/J mice
from the Jackson Laboratory. Cre expression was induced postnatal in 7-week-old
female PTP4A1fl/fl—COL1A1 Cre mice through intraperitoneal injections of 2 mg
tamoxifen dissolved in 100 μl corn oil for 5 consecutive days.
Bleomycin-induced fibrosis model. Experimental dermal fibrosis was induced in
8–12-week-old female mice through seven subcutaneous injections every other day
of 50 μg bleomycin sulfate dissolved in 100 μl phosphate-buffered saline (PBS). In
the PTP4A1fl/fl—COL1A1 Cre mice, bleomycin was injected 3 days after the last
tamoxifen injection. All treatment groups consisted of at least five mice to detect a
significant effect. We focused on female mice exclusively, since SSc overwhelmingly
affects women vs. men. The severity of fibrosis was assessed at the bleomycin
injection sites using an AxioScan Z1 slide scanner (Zeiss, Jena, Germany) on
trichrome-stained skin and lung sections, prepared at the La Jolla Institute histo-
pathology core. The distance between the epidermal–dermal junction and the
dermal–subcutaneous fat junction was calculated in triplicate in three consecutive
skin sections from each animal. Additional fragments of affected skin were used to
assess collagen deposition using the Sircol assay kit from Biocolors (Belfast, UK)
and ACTA2 mRNA expression. No randomization or blinding were used.
Quantitative real-time polymerase chain reaction. RNA was extracted using
mini and micro RNeasy kits from Qiagen (Hilden, Germany). Complementary
DNA (cDNA) was synthesized using the SuperScript III First-Strand Synthesis
System from Thermo Fisher Scientific. qPCR was performed using a LightCycler
480 from Roche (Basel, Switzerland), with individual primer assays and SYBR
Green qPCR Master Mix from Qiagen. Efficiency of the primer assays was guar-
anteed by the manufacturer to be > 90%. Each reaction was analyzed in triplicate
and data were normalized to the expression levels of the housekeeping genes
POLR2A or GAPDH. Absence of genomic DNA contamination was confirmed
using control reactions lacking the reverse transcriptase enzyme during the cDNA
synthesis step.
Western blotting. Cells were lysed in ice-cold RIPA buffer (50 mM TrisHCl [pH
8.0], 150 mM NaCl, 5 mM EDTA, 1% NP40, 0.5% sodium deoxycholate, 0.1%
sodium dodecyl sulfate) or TNE buffer (50 mM TrisHCl [pH 8.0], 150 mM NaCl, 5
mM EDTA) with protease and phosphatase inhibitor cocktails from Roche. Protein
concentrations in cell lysates were determined using a bicinchoninic acid protein
assay kit from Thermo Fisher Scientific. Proteins were loaded on 10% or 4–20%
Tris-Glycine gels from Thermo Fisher Scientific, electrotransferred onto nitro-
cellulose membranes from GE Healthcare Life Sciences (Pittsburgh, PA) and
incubated overnight at 4 °C with specific antibodies (1:1000 dilution in 5% BSA).
Immunoreactivity was revealed by incubation with host-specific secondary anti-
bodies conjugated with horseradish peroxidase (HRP), followed by detection with
Luminata Crescendo Western HRP substrate from EDM Millipore. Images were
acquired using a G:BOX chemi system from Syngene (Frederick, MD) and protein
bands analyzed with the ImageJ software. Protein expression was normalized to the
expression levels of tubulin, GAPDH, or non-phosphorylated corresponding pro-
teins. Uncropped images of the blots are provided in Supplementary Information.
Treatment with cell-permeable antisense oligonucleotide. NHDF and NHLF
fibroblasts were treated for 7 days with 2.5 mM control or targeting ASOs.
PTP4A1 and PTP4A2 ASOs were designed against the pre-mRNA splicing
junction between intron 2 and exon 3. PTP4A1 ASO2 was designed against the
pre-mRNA splicing junction between exon 3 and intron 3. PTP4A1 ASO3 was
designed against the pre-mRNA splicing junction between intron 3 and exon 4.
ASOs were replaced in fresh culture medium after 3 days and in serum-starvation
medium after 6 days. RT-PCR was performed on ASO-treated fibroblasts cDNA
with PTP4A1-specific (forward: 5′-ACAATCCAACCAATGCGACC-3′; reverse:
5′-GCTGTTAAAAGCTCCACGCC-3′) and PTP4A2-specific (forward:
5′-GGAGTGACGACTTTGGTTCG-3′; reverse: 5′-TCAAAGCAAGTGCA
ACCAGC-3′) oligos from IDT (San Diego, CA) using a S1000 thermal cycler from
Bio-Rad (Irvine, CA).
NGS on NHDF. Three NHDF lines were plated in triplicate, incubated with control
or PTP4A1 ASOs and serum-starved for 24 h prior the experiment. RNA was
extracted using micro RNeasy kits from Qiagen and 500 ng of total RNA for each
condition were used to generate mRNA-focused libraries on a Biomek FXP
automation platform from Beckman Coulter (Carlsbad, CA) with the TruSeq-
Stranded mRNA HT Sample Prep Kit from Illumina (San Diego, CA). NGS was
performed at the La Jolla Institute sequencing facility with a Hiseq 2500 from
Illumina.
TGFβ stimulation of fibroblasts. NHDF or NHLF lines were incubated with
control or targeting ASOs, serum-starved for 24 h and stimulated with 20 ng/ml
human TGFβ1 or vehicle as control. Cells were lysed for qPCR or western blotting
24 h or 15 min after TGFβ1 stimulation, respectively.
ERK inhibitor treatment. NHDF lines were serum-starved for 24 h and treated
with 50 μM SCH772984 ERK inhibitor or DMSO as control. Cells were lysed for
SMAD3 qPCR 24 h after the treatment.
SMAD3 localization. NHDF lines were incubated with control ASO, PTP4A1
ASO, PTP4A2 ASO or DMSO, SU6656 SRC, and SCH772984 ERK inhibitors,
serum-starved for 24 h and stimulated with 20 ng/ml human TGFβ1 or vehicle as
control. Thirty minutes after stimulation, cells were fixed in 4% formaldehyde at
RT and permeabilized in PBS with 1% BSA and 0.4% Triton X-100 for 20 min at
RT. Cells were then incubated overnight at 4 °C with rabbit anti-SMAD3 antibody
(1:200 dilution in PBS with 1% BSA and 0.1% Triton X-100), washed and incu-
bated for 1 h with Alexa Fluor 568-conjugated goat anti-rabbit IgG (1:500 dilution
in PBS with 1% BSA and 0.1% Triton X-100). Nuclei were stained for 10 min at RT
with 5 μg/ml Hoechst 33242 from Thermo Fisher Scientific. Sample images were
obtained using a Fluoview FV10i confocal microscope from Olympus. For SMAD3
fluorescence densitometry three different fields were assessed for each NHDF line.
ImageJ software was used for signal quantification.
CHIP qPCR. NHDF lines were incubated with control or PTP4A1 ASO, serum-
starved for 24 h and stimulated with 20 ng/ml human TGFβ1 or vehicle as control.
Then cells were fixed in 1% formaldehyde for 15 min at RT. After sonication,
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chromatin was immunoprecipitated with the ChIP assay kit from Millipore using a
rabbit anti-pSMAD3 (S423/425) antibody overnight at 4 °C. The eluted DNA was
purified with ChIP DNA Clean & Concentrator from Zymo Research (Irvine, CA)
and used for COL1A2 promoter qPCR. 10% input for each condition was used for
normalization. Human COL1A2 promoter primers54, 5′-TCTGCCCATGTCGGG
GCT-3′ (forward) and 5′-TGCCTCCAAAAGGGCCTCC-3′ (reverse), were
purchased from IDT.
Constructs, transfections, and luciferase reporter assays. WT and mutant
PTP4A1 and PTP4A2 human genes cloned in pCDNA4 have been already
described30. ΔPTP4A1, lacking the exon 4 and cloned in the pET28 vector, was
obtained from Genscript (Piscataway, NJ). The expression of 6× histidine-tagged
ΔPTP4A1 was induced for 4 h with 1 mM isopropyl β-D-1-thiogalactopyranoside
in E. coli BL21 (DE3) strain and purified with an IMAC nickel resin and a NGC
Chromatography Systems from Bio-Rad (Hercules, CA). The Cignal SMAD
reporter kit was purchased from Qiagen. Transfections were conducted in HEK
293T cells from ATCC using Lipofectamine 3000 from Thermo Scientific. Cells
were stimulated with 20 ng/ml human TGFβ1 24 h after transfection. Luciferase
activity was assessed using the Dual-Luciferase Reporter Assay System from Pro-
mega (Madison, WI). Renilla luciferase activity was used to normalize firefly
luciferase activity.
Enzymatic and co-precipitation assays. NHDF lines were incubated with control
or targeting ASOs, serum-starved for 24 h and stimulated with 20 ng/ml human
TGFβ1 or vehicle as control. Cells were lysed 15 min after stimulation in ice-cold
TNE buffer and ROCK activity was measured with the Rho-associated kinase
activity assay from EMD Millipore. SRC dephosphorylation was assessed in the
presence of recombinant PTP4A1 or PTP4A2. Briefly, 50 ng of GST-tagged rSRC
was incubated with glutathione sepharose high-performance medium from GE
Healthcare Life Sciences and activated in kinase assay buffer (60 mM HEPES pH
7.5, 5 mM MgCl2, 5 mM MnCl2, 1 mM DTT, 1 mM Na3VO4, 1 mM ATP) for 10
min at 30 °C in agitation. The rSRC-medium reaction complex was washed and
incubated with 1.5 μM rPTP4A1, rPTP4A2, or BSA as control in 60 mM HEPES
pH 7.5, 5 mM MgCl2, 5 mM MnCl2, 1 mM DTT for 2 h at 37 °C in agitation. The
beads were then either assessed for rSRC phosphorylation on Y416 or washed for
assessing whether rPTP4A1, ΔPTP4A1, or rPTP4A2 were bound to rSRC. For
kinase assays in the presence of PTP4A1 and PTP4A2, 50 ng of rSRC was incu-
bated in kinase assay buffer (60 mM HEPES pH 7.5, 5 mM MgCl2, 5 mM MnCl2, 1
mM DTT) together with 1.5 μM rPTP4A1, rPTP4A2, or BSA as control. rSRC was
then assessed for its phosphorylation on Y416 as described above. For CSK kinase
assay, 20 ng of rSRC was incubated at 30 °C for 2 h in kinase assay buffer (60 mM
HEPES pH 7.5, 5 mM MgCl2, 5 mM MnCl2, 1 mM DTT, 1 mM Na3VO4, 1 mM
ATP) together with 50 ng rCSK, 100 ng rPTP4A1, and 200 ng rCD45. rSRC was
then assessed for its phosphorylation on Y527 as described above.
PTP4A1 enzymatic activity. 40 µg/ml of BSA, wtPTP4A1, or ΔPTP4A1 were
incubated at 37 °C for 8 h with 5 mM p-nitrophenyl phosphate in 50 mM HEPES,
10 mM DTT, pH 7.5. Absorbance at 410 nm was recorded with an Infinite M1000
(Tecan, San Jose, CA) and specific activity was reported as pmol/min/µg.
Immunoprecipitation. HA-tagged PTP4A1 WT and C104S cloned in pCDNA4
vector30 or HA-tagged PTP4A2 WT and C101S cloned in pCDNA4 vector
(obtained from Mutagenex [Suwanee, GA]) were transfected in HEK 293T cells
(ATCC) using Lipofectamine 3000 from Thermo Scientific. 48 h after transfection,
cells were lysed in ice-cold TNE buffer with a protease inhibitor cocktail from
Roche and 10 mM Na3VO4, then incubated for 2 h at 4 °C with rabbit anti-SRC or
anti-HA antibody 1:100 and immunoprecipitated 2 h at 4 °C on protein G
Sepharose 4 fast flow from GE Healthcare Life Sciences. The co-precipitation of
HA-tagged PTP4A1 or PTP4A2 with SRC was assessed by western blotting.
Statistical analysis. Sample sizes were selected based on our experience with the
above-mentioned assays in order to achieve sufficient power to detect biologically
relevant differences in the experiments being conducted with an α error (two-
tailed) <0.05. The two-tailed Mann–Whitney test or the two-tailed Welch’s t-test
were performed where appropriate as reported in the figure legends. For experi-
ments where variance was not similar between the groups being compared, the
two-tailed Wilcoxon test or the two-tailed paired t-test were used. A comparison
was considered significant if p was less than 0.05. All statistical analyses were
performed using GraphPad Prism software. Raw data sets for the figures in main
text are provided in Supplementary Data 1. Raw data sets for the figures in Sup-
plementary Information are provided in Supplementary Data 2.
NGS differential expression was analyzed with DeSeq software and genes with
threshold expression higher than 100, log2 fold change expression higher than 0.5
and adjusted p-values less than 0.01 were considered significantly affected by
PTP4A1 silencing in NHDF lines. NGS molecular functions, biological processes,
and cellular compartments analysis were performed with GO-Elite software.
Data availability. Sequence data that support the findings of this study have been
deposited in GEO with the primary accession code GSE102864. The authors
declare that all other data supporting the findings of this study are available within
the article and its Supplementary Information files.
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